Oral Cytovene data

A study of oral Cytovene published in AIDS showed that the drug reduced the incidence of sepsis and catheter-related events compared to intravenously administered ganciclovir.

In a 20-week, open-label trial in 159 HIV-positive patients in Europe and Australia, CMV retinitis progressed in 72 percent of patients in the oral Cytovene group versus 76 percent in the IV ganciclovir group. Mean time to progression was 51 days with the oral drug versus 62 days with the IV drug. ...